

INVIVO THERAPEUTICS HOLDINGS CORP.

Form S-8

May 31, 2013

As filed with the Securities and Exchange Commission on May 31, 2013

Registration No. 333-

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8
REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

INVIVO THERAPEUTICS HOLDINGS CORP.

(Exact Name of Registrant as Specified in Its Charter)

Nevada
(State or Other Jurisdiction of
Incorporation or Organization)

36-4528166
(I.R.S. Employer
Identification No.)

One Kendall Square

Building 1400 East, Floor 4

Cambridge, MA 02139

(Address of Principal Executive Offices) (Zip Code)

InVivo Therapeutics Holdings Corp. 2010 Equity Incentive Plan

(Full Title of the Plan)

Francis M. Reynolds

Chief Executive Officer

InVivo Therapeutics Holdings Corp.

One Kendall Square

Building 1400 East, Floor 4

Cambridge, Massachusetts 02139

(Name and Address of Agent for Service)

(617) 863-5500

(Telephone Number, Including Area Code, of Agent For Service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input checked="" type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/> (Do not check if a smaller reporting company)	Smaller reporting company	<input type="checkbox"/>

CALCULATION OF REGISTRATION FEE

Title of securities to be registered	Amount to be registered (1)	Proposed maximum offering price	Proposed maximum aggregate	Amount of registration fee
---	--	--	---	---------------------------------------

Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form S-8

		per share (2)	offering price (2)	
Common Stock, \$0.00001 par value per share	4,500,000 Shares	\$3.08	\$13,860,000	\$1,891
Total	4,500,000 Shares		\$13,860,000	\$1,891

- (1) Pursuant to Rule 416 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional shares of Common Stock that become issuable under the InVivo Therapeutics Holdings Corp. 2010 Equity Incentive Plan by reason of any stock dividend, stock split, recapitalization, or any other similar transaction without receipt of consideration that results in an increase in the number of outstanding shares of Common Stock of the Registrant.
- (2) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) of the Securities Act, based upon the average of the high and low sale prices of the Registrant's Common Stock quoted on the OTC Bulletin Board on May 28, 2013 (\$3.08), in accordance with Rule 457(c) under the Securities Act of 1933, as amended.

REGISTRATION OF ADDITIONAL SECURITIES

PURSUANT TO GENERAL INSTRUCTION E

This registration statement is being filed to register an additional 4,500,000 shares of the Common Stock of InVivo Therapeutics Holdings Corp. (the Registrant) that may be issued under the InVivo Therapeutics Holdings Corp. 2010 Equity Incentive Plan (the Plan). The Registrant has previously filed registration statements relating to 3,500,000 shares of its Common Stock issuable under the Plan (File No. 333-176110 filed on August 5, 2011) and an additional 3,000,000 shares of its Common Stock issuable under the Plan (File No. 333-183491 filed on August 22, 2012). Pursuant to General Instruction E of Form S-8, the Registrant hereby incorporates by reference the contents of these prior registration statements, except for Items 3 and 8 which are being updated by this registration statement.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents filed with the SEC are incorporated by reference in this registration statement:

- (a) The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, filed with the SEC on March 12, 2013;
- (b) All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), since December 31, 2012; and
- (c) The description of the Registrant's Common Stock contained in the Registrant's Registration Statement on Form 8-A filed with the SEC on June 30, 2006, including any amendments or reports filed for the purpose of updating that description.

In addition, all documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date hereof and prior to the filing of a post-effective amendment which indicates that all securities offered herein have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing such documents. Any statement contained herein or in a document incorporated by reference or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that such statement is modified or superseded by any other subsequently filed document which is incorporated or is deemed to be incorporated by reference herein. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

Item 8. Exhibits.

The Exhibit Index immediately preceding the exhibits is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Cambridge, Massachusetts, on May 31, 2013.

INVIVO THERAPEUTICS HOLDINGS CORP.

By: /s/ Francis M. Reynolds
Francis M. Reynolds
Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints Francis M. Reynolds as such person's true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto, and all documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or any substitute or substitutes of him, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

/s/ Francis M. Reynolds	Chairman, Chief Executive Officer,	May 31, 2013
Francis M. Reynolds	President and Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)	
/s/ Kenneth DiPietro	Director	May 31, 2013
Kenneth DiPietro		
/s/ John A. McCarthy, Jr.	Director	May 31, 2013
John A. McCarthy, Jr.		
/s/ Richard J. Roberts	Director	May 31, 2013
Dr. Richard J. Roberts		

EXHIBIT INDEX

No.	Description
4.1	InVivo Therapeutics Holdings Corp. 2010 Equity Incentive Plan, as amended (Incorporated by reference to Appendix A of the Registrant's Definitive Proxy Statement on Schedule 14A, as filed with the SEC on April 19, 2013).
5.1	Opinion of Greenberg Traurig, LLP, counsel to the Registrant.
23.1	Consent of Greenberg Traurig, LLP (included in Exhibit 5.1).
23.2	Consent of Wolf & Company, P.C.
24.1	Power of attorney (included on the signature page to this registration statement).